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Introduction
In 2005 the European Respiratory Society (ERS), in collabo-
ration with The European Society for Clinical Microbiology
and Infectious Diseases (ESCMID), published guidelines on
the management of lower respiratory tract infections (LRTIs)
in adults [1]. This document was based on published scien-
tiﬁc literature up to the end of 2002. We have now updated
these guidelines to include publications to May 2010. The
taskforce responsible for guideline development has been
sponsored by the ERS and ESCMID. Members of the task-
force are members of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommenda-
tions for the most common management questions occurring
in routine clinical practice in the management of adult
patients with LRTI. The target audience for the guidelines is
thus all those whose routine practice includes the manage-
ment of adult LRTI.
This short document covers only the statements and rec-
ommendations in the guidelines. A much more detailed doc-
ument, including not only the recommendations but also
background information for each recommendation with
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details about each new cited reference and the evidence
grades, is available on the ERS and ESCMID websites. Both
documents are divided into background information about
microbial causes, antibiotic resistance and pharmacodynam-
ics, and then the guideline section, which captures manage-
ment outside hospital, management inside hospital (including
community-acquired pneumonia (CAP), acute exacerbations
of chronic obstructive pulmonary disease (AECOPD) and
acute exacerbations of bronchiectasis) and prevention. The
guidelines are about the management of infection. This
means that for conditions such as AECOPD, aspects of man-
agement that are unrelated to infection (e.g. use of steroids
or bronchodilators) are not included.
Because this is an update, original data and publications
have usually not been repeated and the reader is referred to
the original publication [1] for this.
Methods
Using the same search ﬁlter as for the 2005 document (this is
described in detail in the previous publication [1] and website
documents—http://www.ersnet.org; http://www.escmid.org)
we identiﬁed relevant manuscripts in PubMed published from
July 2002 to May 2010. We retrieved 15 261 titles and loaded
them into an electronic database. From these, 1677 titles were
identiﬁed as potentially relevant publications by the expert
panel members. The same process of evidence appraisal and
grading and recommendation development and grading as in
the 2005 document was used. As this is an update using the same
methodologies, the layout of the document, including text, rec-
ommendations and evidence tables, is the same as 2005.
The document takes each clinical question for which there
was a recommendation in the 2005 guideline and presents
new information when available followed by a new recom-
mendation. In some circumstances, because of lack of new
evidence, or sometimes even in the presence of new evi-
dence, the recommendation is unchanged from 2005. Where
this is the case it is indicated.
In some parts of the guidelines new questions and
recommendations have been added to cover relevant areas not
included in the 2005 guidelines (e.g. aspiration pneumonia).
LRTI Deﬁnitions
The guidelines are to be used to guide the management of adults
with lower respiratory tract infection (LRTI). As will be seen in
the following text, this diagnosis, and the other clinical syn-
dromes within this grouping, can be difﬁcult to make accurately.
In the absence of agreed deﬁnitions of these syndromes these
guidelines are to be used when, in the opinion of a clinician, an
LRTI syndrome is present. The following are put forward as def-
initions to guide the clinician, but it will be seen in the ensuing
text that some of these labels will always be inaccurate. These
deﬁnitions are pragmatic and based on a synthesis of available
studies. They are primarily meant to be simple to apply in clini-
cal practice, and this might be at the expense of scientiﬁc accu-
racy. These deﬁnitions are not mutually exclusive, with lower
respiratory tract infection being an umbrella term that includes
all others, which can also be used for cases that cannot be classi-
ﬁed into one of the other groups. No new evidence has been
identiﬁed that would lead to a change in the clinical deﬁnitions,
which are therefore unchanged from the 2005 publication.
Since the publication of the 2005 guidelines the term health
care-associated pneumonia (HCAP) has been put forward to
capture groups of patients with pneumonia, some acquired
outside hospital, expected to be caused by similar pathogens,
but different from those usually found in community-acquired
LRTI. In the opinion of the taskforce members the evidence
base does not support the use of this term as being clinically
relevant in Europe at the present time. HCAP is therefore not
covered further in this document [2–17].
Lower respiratory tract infection
An acute illness (present for 21 days or less), usually with
cough as the main symptom, with at least one other lower
respiratory tract symptom (sputum production, dyspnoea,
wheeze or chest discomfort/pain) and no alternative explana-
tion (e.g. sinusitis or asthma).
Acute bronchitis (AB)
An acute illness, occurring in a patient without chronic lung
disease, with symptoms including cough, which may or may
not be productive and associated with other symptoms or
clinical signs that suggest LRTI, and no alternative explanation
(e.g. sinusitis or asthma).
Inﬂuenza
An acute illness, usually with fever, together with the presence
of one or more of headache, myalgia, cough and sore throat.
Suspected community-acquired pneumonia (CAP)
An acute illness with cough and at least one of new focal
chest signs, fever >4 days or dyspnoea/tachypnoea, and with-
out other obvious cause.
Deﬁnite community-acquired pneumonia (CAP)
As above but supported by chest radiograph ﬁndings of
lung shadowing that is likely to be new. In the elderly, the
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presence of chest radiograph shadowing accompanied by acute
clinical illness (unspeciﬁed) without other obvious cause.
Acute exacerbation of COPD (AECOPD)
An event in the natural course of the disease characterized
by a worsening of the patient’s baseline dyspnoea, cough
and/or sputum beyond day-to-day variability sufﬁcient to
warrant a change in management. If chest radiograph shad-
owing, consistent with infection, is present the patient is
considered to have CAP.
Acute exacerbation of bronchiectasis (AEBX)
In a patient with features that suggest bronchiectasis, an
event in the natural course of the disease characterized by a
worsening in the patient’s baseline dyspnoea and/or cough
and/or sputum beyond day-to-day variability sufﬁcient to
warrant a change in management. If chest radiograph shad-
owing, consistent with infection, is present the patient is
considered to have CAP.
Background
What new information is available about the
microbiological causes of LRTI?
There has been no major change in causative pathogens for
LRTI. More information is available about the frequency of
polymicrobial infections, including viral infections. PVL-produc-
ing Staphylococcus aureus has emerged as a new cause, often of
severe CAP, but currently remains uncommon [18–90].
What information is available about the frequency and clini-
cal relevance of antimicrobial resistance in these settings?
1 In pneumococci, erythromycin MICs >0.5 mg/L predict
clinical failure. The prevalence of resistance (R) in many
countries compromises the efﬁcacy of macrolides in the
treatment of pneumococcal infection. The prevalence of
resistance will dictate the need to reassess current rec-
ommendations for the treatment of CAP.
2 Adequate choice and dosing of selected b-lactams is still
useful in the treatment of extrameningeal pneumococcal
infections. No documented failures in patients with ext-
rameningeal infections due to penicillin R strains treated
with adequate doses of penicillins and third generation
cephalosporins. Penicillin, 2 g (3.2 mU) i.v. Q 4 h, should
be adequate for strains with a penicillin MIC of £8 mg/L;
adjust dose for renal impairment; ceftriaxone 1 g i.v. or
i.m. Q 12 h or cefotaxime 2 g i.v. Q 6 h, should be ade-
quate for strains with n MIC of £8 mg/L. New formula-
tion of amoxicillin/clavulanate (2 g/125 Q 12 h)
eradicated amoxicillin-resistant strains (MICs, 4–8 mg/L)
in two randomized controlled trials. Oral cephalosporins
are not adequate for the treatment of infection caused
by strains with penicillin MICs >2 mg/L.
3 Fluoroquinolones are highly active and efﬁcacious against
respiratory pathogens; they should be used in well-deﬁned
circumstances. If the prevalence of ﬁrst step mutants is
low, the use of the most potent FQ is a logical choice if
resistance has to be avoided/delayed. Previous exposure
to an FQ in the recent past precludes the use of a member
of this class for the empirical treatment of CAP.
4 Macrolides show, at best, only modest activity against
H. inﬂuenzae. The existence of efﬂux pumps leads to loss
of susceptibility to this class in more than 98% of H. inﬂu-
enzae strains.
5 Among ‘atypicals’, antibiotic resistance is rare and very
seldom responsible for clinical failures.
6 Macrolide resistance in Mycoplasma pneumoniae is rising
in Japan; there is a need for European local surveillance
studies.
7 The role of community-acquired meticillin-resistant
Staphylococcus aures (CA-MRSA) in CAP is poorly
deﬁned, although emergent in Europe. CA-MRSA is usu-
ally only resistant to the b-lactams and susceptible to
most other antibiotic classes. The antibiotic treatment of
CA-MRSA pneumonia is not known. As suppression of
toxin production may correlate with improved outcome,
vancomycin alone may not be the optimal treatment for
pneumonia. Thus, the combination of a bactericidal agent
with a toxin-suppressing agent, such as clindamycin or
linezolid, has been suggested as the optimal choice.
8 The in vivo selection of resistance that results from inap-
propriate antimicrobial therapy is a warning that empha-
sizes the importance of the proper use of antimicrobials
[91–128].
What new information is available about antimicrobial
pharmacokinetics and pharmacodynamics?
The only new information is about the need for high levo-
ﬂoxacin doses (750 mg once daily) in the treatment of Pseu-
domonas and Klebsiella [129,130]. Two other new studies do
now alter the current guideline recommendations [131,132].
Management Outside Hospital
Introduction
Lower respiratory tract infection is a broad description of a
group of disease entities, encompassing acute bronchitis, pneu-
monia and exacerbations of chronic lung disease. In primary
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care it is very difﬁcult to differentiate between those different
diseases without doing extensive additional diagnostic tests.
Patients can present with cough, dyspnoea, tachypnoea, fever,
pain in the chest, wheezing and auscultatory abnormalities.
There is huge overlap in presentation between the different
lower respiratory diseases mentioned above and it is neither
feasible nor cost-efﬁcient to do a full diagnostic work-up in all
patients. Therefore an empirical and pragmatic approach is
warranted. The statements and recommendations below are
based on primary care studies, expert opinion and consensus
among members of the working group.
Diagnosis
When should aspiration pneumonia be considered? ‘Aspiration
pneumonia should be considered in patients with difﬁculties
with swallowing who show signs of an acute LRTI. In these
patients a chest X-ray should be performed’ [C3].
No new information. Recommendation not changed.
When should left ventricular failure be considered? ‘Left ven-
tricular failure should be considered in patients above 65,
with either orthopnoea, displaced apex beat and/or a his-
tory of myocardial infarction, hypertension or atrial ﬁbrilla-
tion’.
‘Low serum levels of Atrial Natriuretic Peptide (BNP
<40 pg/mL) or NT pro-BNP <150 pg/mg) make the presence
of left ventricular failure unlikely’ [C3].
New information. Recommendation not changed [133–135].
When should pulmonary embolism be considered? ‘Pulmonary
embolism should be considered in patients with one of the
following characteristics: a history of DVT or pulmonary
embolism, immobilization in the past 4 weeks, or malignant
disease’ [C3].
No new information. Recommendation not changed.
When should chronic airway disease be considered? ‘In patients
with a persistent cough and at least two of the following,
wheezing (either as sign or as symptom), previous consulta-
tions for wheezing or cough, dyspnoea, prolonged expiration,
a smoking history and symptoms of allergy, lung-function
tests should be considered to assess the presence of chronic
airway disease. In elderly patients who smoke and present
with a cough, COPD should be considered’ [B1] [136,137].
How to differentiate between pneumonia and other respiratory
tract infections. ‘A patient should be suspected of having
pneumonia when one of the following signs and symptoms
are present: new focal chest signs, dyspnoea, tachypnoea,
pulse rate >100 or fever >4 days. In patients with a
suspected pneumonia a test for serum-level of C-reactive
protein (CRP) can be done. A level of CRP <20 mg/L at pre-
sentation, with symptoms for >24 h, makes the presence of
pneumonia highly unlikely; a level of >100 mg/L makes pneu-
monia likely’.
‘In case of persisting doubt after CRP testing, a chest X-
ray should be considered to conﬁrm or reject the diagnosis’
[B1] [138–143].
Should the primary care physician test for a possible microbiologi-
cal aetiology of LRTI? ‘Microbiological tests such as cultures
and gram stains are not recommended’ [B1].
‘Biomarkers to assess the presence of a bacterial pathogen
are not recommended in primary care’ [A1] [141,142,144].
New information. Recommendation not changed.
Prognosis
How should the risk of complications be assessed in a primary
care patient with LRTI? ‘Patients with an elevated risk of
complications should be monitored carefully and referral
should be considered. In patients over 65 years of age the
following characteristics are associated with a complicated
course: presence of COPD, diabetes or heart failure, previ-
ous hospitalization in the past year, taking oral glucosteroids,
antibiotic use in the previous month, general malaise,
absence of upper respiratory symptoms, confusion/dimin-
ished consciousness, pulse >100, temperature >38, respira-
tory rate >30, blood pressure <90/60, and when the
primary care physician diagnoses pneumonia [A3]. In patients
under 65 the working group thinks that diabetes, a diagnosis
of pneumonia and possibly also asthma are risk factors for
complications. For all age groups, serious conditions such as
active malignant disease, liver and renal disease and other
disorders that are relatively rare in primary care but affect
immunocompetence, do also increase risk of complications’
[C3] [145–150].
Treatment
Should symptomatic acute cough be treated? ‘Cough suppres-
sants, expectorants, mucolytics, antihistamines, inhaled corti-
costeroids and bronchodilators should not be prescribed in
acute LRTI in primary care’ [A1] [151–153].
When should antibiotic treatment be considered in patients with
LRTI? Antibiotic treatment should be prescribed in patients
with suspected or deﬁnite pneumonia (see How to differenti-
ate between pneumonia and other respiratory tract infec-
tions) [C1].
Antibiotic treatment should be considered for patients
with LRTI and serious comorbidity such as:
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1 selected exacerbations of COPD; (see below)
2 cardiac failure;
3 insulin-dependent diabetes mellitus;
4 a serious neurological disorder (stroke etc.) [C3]
[154,155].
What are the indications for antibiotic treatment of acute exacer-
bations of chronic obstructive lung disease (COPD)? ‘An antibiotic
should be given in exacerbations of COPD in patients with
all three of the following symptoms: increased dyspnoea,
sputum volume and sputum purulence. In addition, antibiotics
should be considered for exacerbations in patients with
severe COPD’ [C1].
New information. Recommendation not changed [156].
Which antibiotics should be used in patients with LRTI? ‘Amoxi-
cillin or tetracycline should be used as the antibiotic of ﬁrst
choice based on least chance of harm and wide experience in
clinical practice. In the case of hypersensitivity, a tetracycline
or macrolide such as azithromycin, clarithromycin, erythromy-
cin or roxithromycin is a good alternative in countries with
low pneumococcal macrolide resistance. National/local resis-
tance rates should be considered when choosing a particular
antibiotic. When there are clinically relevant bacterial resis-
tance rates against all ﬁrst choice agents, treatment with levo-
ﬂoxacin or moxiﬂoxacin may be considered’ [C1] [157,158].
Is antiviral treatment useful in patients with LRTI? ‘The empiri-
cal use of antiviral treatment in patients suspected of having
inﬂuenza is usually not recommended [B1]. Only in high-risk
patients who have typical inﬂuenza symptoms (fever, muscle
ache, general malaise and respiratory tract infection), for
<2 days and during a known inﬂuenza epidemic, can antiviral
treatment can be considered’ [A1].
New information. Recommendation not changed [159,160].
How should patients with LRTI be monitored? ‘A patient
should be advised to return if the symptoms take longer
than 3 weeks to disappear’.
‘Clinical effect of antibiotic treatment should be expected
within 3 days and patients should be instructed to contact their
doctor if this effect is not noticeable. Seriously ill patients, mean-
ing those with suspected pneumonia and elderly with relevant
co-morbidity, should be followed-up 2 days after the ﬁrst visit’.
‘All patients or persons in their environment should be
advised to contact their doctor again if fever exceeds 4 days,
dyspnoea gets worse, patients stop drinking or consciousness
is decreasing’ [C3].
No new information. Recommendation rephrased.
When should patients with LRTI be referred to hospital? In the
following categories of patients, referral to hospital should
be considered.
1 Severely ill patients with suspected pneumonia (the fol-
lowing signs and symptoms are especially relevant here:
tachypnoea, tachycardia, hypotension and confusion).
2 Patients with pneumonia who fail to respond to antibiotic
treatment.
3 Elderly patients with pneumonia and elevated risk of
complications, notably those with relevant co-morbidity
(diabetes, heart failure, moderate and severe COPD,
liver disease, renal disease or malignant disease).
4 Patients suspected of pulmonary embolism.
5 Patients suspected of malignant disease of the lung [C3].
These recommendations are based on consensus in the
working group. There are no studies comparing different
referral strategies.
Management Inside Hospital
Community-acquired pneumonia
Who should be admitted to hospital? ‘The decision to hospi-
talize remains a clinical decision. However, this decision
should be validated against an objective tool of risk assess-
ment. The CRB-65 is most practical in its simplicity. In
patients meeting a CRB-65 of one or more (except age ‡65
as the only criterion met), hospitalization should be seriously
considered [A3]. Biomarkers (e.g. CRP or procalcitonin)
have a signiﬁcant potential to improve severity assessment
but have not been sufﬁciently evaluated for the decision to
hospitalize. [A3] [141,145,161–191].
Who should be considered for ICU admission? ‘Findings reﬂect-
ing acute respiratory failure, severe sepsis or septic shock
and radiographic extension of inﬁltrates, as well as severely
decompensated comorbities, should prompt consideration of
admission to the ICU or an intermediate care unit’ [A3].
‘The predictive potential of rules for the prediction of
ICU admission depends on local facilities. Therefore, it
appears that severity criteria should be used to indicate the
need for intensive care treatment rather than care in a spe-
cial unit’.
‘The presence of at least two of systolic blood pressure
<90 mmHg, severe respiratory failure (PaO2/FIO2 <250) or
involvement of >2 lobes on chest radiograph (multilobar
involvement), or one of requirement for mechanical ventila-
tion or requirement for vasopressors >4 h (septic shock),
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indicates severe CAP. Alternatively, the presence of several
minor criteria as provided in the last IDSA/ATS update may
indicate severe CAP.’ [A3].
‘Both rules should increase the attention given to the rec-
ognition of patients with unstable courses of pneumonia in
order to avoid delayed transfer to the ICU’ [192–200].
What is the value of blood cultures in the diagnosis of commu-
nity-acquired pneumonia? ‘Two sets of blood cultures should
be performed in all patients with CAP who require hospital-
ization’ [A3].
New information. Recommendation not changed [61,201–
205].
What other invasive techniques for normally sterile specimens can
be useful in the laboratory diagnosis of pneumonia? (a) Thora-
centesis: diagnostic thoracentesis should be performed in hos-
pitalized patients with CAP when a signiﬁcant (as judged by
the admitting physician) pleural effusion is present [A3].
No new information. Recommendation not changed.
(b) Transthoracic needle aspiration (TNA): because of the
inherent potential adverse effects, TNA can be con-
sidered ONLY on an individual basis for some
severely ill patients, with a focal inﬁltrate, in whom
less invasive measures have been non-diagnostic [A3].
No new information. Recommendation not changed.
(c) Bronchoscopic protected specimen brush (PSB) and bronc-
hoalveolar lavage (BAL) and quantitative endotracheal aspi-
rates (QEA): BAL should be the preferred technique in
non-resolving pneumonia [A3].
‘Bronchoscopic sampling of the lower respiratory
tract can be considered in intubated patients and selected
non-intubated patients, where gas exchange status allows’
[A3].
New information. Recommendation not changed [206].
What is the value of sputum examination? Gram strain: should
be performed when a purulent sputum sample can be
obtained from patients with CAP and processed in a timely
manner. The presence of a predominant bacterial morpho-
type allows inference of the aetiological bacterial species and
interpretation of the results of sputum culture [A3].
New information. Recommendation not changed [207–
213].
Culture: a culture from a purulent sputum specimen of a
bacterial species compatible with the morphotype observed
in the Gram stain, which is processed correctly, should be
considered for conﬁrmation of the species identiﬁcation and
antibiotic susceptibility testing [B3].
No new information. Recommendation not changed.
What can antigen tests offer in the diagnosis of community acquired
pneumonia? ‘The immunochromatographic urinary antigen
test for S. pneumoniae should be performed in patients admit-
ted to the hospital for reasons of illness severity. This test
should also be considered whenever a pleural ﬂuid sample is
obtained in the setting of a parapneumonic effusion’ [A3].
‘Urine L. pneumophila serogroup 1 antigen detection
should be performed in patients admitted to the hospital for
reasons of severity and in other patients where this infection
is clinically or epidemiologically suspected [A3]. L. pneumophila
serogroup 1 antigen detection in urine is the most rapid
method to diagnose or exclude the infection. A negative test
makes legionella unlikely, but does not exclude legionella
infection’ [A3] [209,214–242].
What can serological tests offer in the diagnosis of pneumo-
nia? ‘Serology for infections caused by M. pneumoniae,
C. pneumoniae and Legionella is more useful in epidemiological
studies than in the routine management of the individual
patient. If aetiological diagnosis of the atypical agents is con-
sidered in the management of the individual patient (e.g. in
patients not responding to b-lactam therapy), serological
tests should not be performed as the only routine diagnostic
test [A3]. A combination of IgM antibody detection and PCR
may be the most sensitive approach’ [A3] [243–250].
Are ampliﬁcation tests useful for the diagnosis of LRTI? Where
available, application of quantitative molecular tests for the
detection of Streptococcus pneumoniae, both in sputum and in
blood, may be valuable in CAP patients in whom antibiotic
therapy has been initiated and may be a useful tool for
severity assessment. Application of molecular tests for the
detection of inﬂuenza and respiratory syncytial virus should
be considered during the winter season and for the detec-
tion of atypical pathogens provided the tests are validated
and the results can be obtained sufﬁciently rapidly to be
therapeutically relevant’ [A3] [18,246–249,251–266].
What classiﬁcation should be used for treatment? ‘Antimicro-
bial treatment has to be empirical and should follow an
approach according to the individual risk of mortality. The
assessment of severity according to mild, moderate and
severe pneumonia implies a decision about the most appro-
priate treatment setting (ambulatory, hospital ward or ICU)
[A4]. Antimicrobial treatment should be initiated as soon as
possible [A3]’.
When should antibiotics be administered after diagnosis of pneu-
monia? ‘Antibiotic treatment should be initiated immediately
after diagnosis of CAP [C3]. In patients with CAP and septic
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shock, delay must not be more than 1 h after diagnosis [A1]’
[267–273].
What initial empirical treatments are recommended? Treatment
options for hospitalized patients with community-acquired pneu-
monia (no need for intensive care treatment) (in alphabetical
order) [C4].
Aminopenicillin ± macrolidea,b
Aminopenicillin/b-lactamase inhibitora ± macrolideb
Non-antipseudomonal cephalosporin
Cefotaxime or ceftriaxone ± macrolideb
Levoﬂoxacina
Moxiﬂoxacina,c
Penicillin G ± macrolide
aCan be applied as sequential treatment using the same drug.
bNew macrolides preferred to erythromycin.
cWithin the ﬂuoroquinolones, moxiﬂoxacin has the highest antipneumococcal
activity.
dIn patients at risk of gram-negative enteric bacterium, particularly strains with
extended-spectrum b-lactamase, but without risk (or after exclusion) of P. aeru-
ginosa, ertapenem may be used [100,158,274–304].
Treatment options for patients with severe community-acquired
pneumonia [C4] (ICU or intermediate care).
No risk factors for P. aeruginosa
Non-antipseudomonal cephalosporin III + macrolidea
or
moxiﬂoxacin or levoﬂoxacin ± non-antipseudomonal cephalosporin III
Risk factors for P. aeruginosa
Antipseudomonal cephalosporinb or acylureidopenicillin/b-lactamaseinhibitor or
carbapenem (meropenem preferred, up to 6 g possible, 3 · 2 in 3-h infusion)
PLUS
ciproﬂoxacinc OR
PLUS
macrolidea + aminoglycoside (gentamicin, tobramycin or amikacin)
aNew macrolides preferred to erythromycin.
bCeftazidime has to be combined with penicillin G for coverage of S. pneumo-
niae.
cLevoﬂoxacin 750 mg/24 h or 500 mg twice daily is an alternative and also cov-
ers Gram-positive bacteria if treatment is empirical [301,305–315].
What is the recommended treatment for speciﬁc identiﬁed
pathogens?
Pathogen Recommended treatment
Highly resistant
S. pneumoniae
(>8 mg/dL)
Levoﬂoxacin
Moxiﬂoxacin
Vancomycin, teicoplanin
Linezolid
MSSA Flucloxacillin
Cephalosporin II
Clindamycin
Levoﬂoxacin
Moxiﬂoxacin
MRSA Vancomycin, teicoplanin ± rifampin
Linezolid
(Clindamycin if sensitive)
Ampicillin-resistant
H. inﬂuenzae
Aminopenicillin plus b-lactamase inhibitor
Levoﬂoxacin
Moxiﬂoxacin
Mycoplasma pneumoniae Doxycycline
Macrolide
Levoﬂoxacin
Moxiﬂoxacin
Chlamydophila pneumoniae Doxycycline
Macrolide
Levoﬂoxacin
Moxiﬂoxacin
Legionella spp. Levoﬂoxacin
Moxiﬂoxacin (most data available for levoﬂoxacin)
Macrolide (azithromycin preferred)
± Rifampicin
Coxiella burnetii Doxycycline
Levoﬂoxacin
Moxiﬂoxacin
Acinetobacter baumanii Third-generation cephalosporin + aminoglycoside
Ampicillin-sulbactam
No experience in pneumonia for tigecycline [99,316–322].
What should be the duration of treatment? The duration of
treatment should generally not exceed 8 days in a respond-
ing patient [C2]. Biomarkers, particularly PCT, may guide
shorter treatment duration [323–331].
When should intravenous treatment be used and when should the
switch to oral occur? In ambulatory pneumonia, treatment
can be applied orally from the beginning [A3]. Some carefully
selected hospital inpatients may also be candidates for exclu-
sively oral treatment.
‘In hospitalized patients, sequential treatment should be
considered in all patients except the most severely ill. The
optimal time to switch to oral treatment is also unknown;
this decision should be guided by the resolution of the most
prominent clinical features at admission [A3]. In most
patients it is probably not necessary to observe patients in
hospital after having switched to oral treatment [A3].
Switch to oral treatment after reaching clinical stability is
also safe in patients with severe pneumonia’ [A2] [332–
338].
Which additional therapies are recommended? ‘All patients
should be subject to early mobilization’ [A3].
‘Low molecular weight heparin should be given in patients
with acute respiratory failure [A3]. The use of non-invasive
ventilation is not yet standard care but can be consid-
ered, particularly in patients with COPD [B3] and ARDS’
[A3].
‘The treatment of severe sepsis and septic shock is con-
ﬁned to supportive measures’ [A3].
‘Steroids are not recommended in the treatment of pneu-
monia [339–347]’ [A3].
When should aspiration pneumonia be suspected? There is no
agreed deﬁnition. Aspiration pneumonia should be suspected
in those with CAP which either:
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1 follows an episode of witnessed aspiration; or
2 occurs in the presence of risk factors for aspiration,
including reduced consciousness level, and dysphagia due
to mechanical or neurological upper digestive tract dys-
function [C3] [6,44,348–355].
Evidence Table
What empirical antibiotic treatment is recommended for aspira-
tion pneumonia?
Hospital ward, admitted from home ICU or admitted from nursing home
Oral or i.v.
b-lactam/b-lactamase inhibitor
or
Clindamycin
or
i.v. cephalosporin + oral metronidazole
or
moxiﬂoxacin
Clindamycin + cephalosporin
or
Cephalosporin + metronidazole
Refs. [6,44,351,352,356–361].
How should response be assessed and when should chest radio-
graph be repeated? ‘Response to treatment should be moni-
tored by simple clinical criteria, including body temperature,
respiratory and haemodynamic parameters. The same parame-
ters should be applied to judge suitability for hospital discharge
[A3]. Complete response, including radiographical resolution,
requires longer time periods. C-reactive protein should be
measured on days one and three/four, especially in those with
unfavourable clinical parameters. The same clinical parameters
should be applied to judge suitability for hospital discharge
[A3]. Discharge decisions should be based on robust markers
of clinical stabilization [A3]’ [176,199,362–365].
How should the non-responding patient be assessed? ‘Two
types of treatment failures, non-responding pneumonia and
slowly resolving pneumonia, should be differentiated [A3].
Non-responding pneumonia occurring in the ﬁrst 72 h of
admission is usually due to antimicrobial resistance or an
unusually virulent organism or a host defence defect or
wrong diagnosis. Non-response after 72 h is usually due to a
complication. The evaluation of non-responding pneumonia
depends on the clinical condition. There are no trials of dif-
ferent approaches to the non-responding patient to guide
this recommendation. In unstable patients, full reinvestigation
followed by a second empirical antimicrobial treatment regi-
men should be carried out. The latter may be withheld in
stable patients. Slowly resolving pneumonia should be rein-
vestigated according to clinical needs, the condition of the
patient and his individual risk factors [C3]’.
Exacerbations of chronic obstructive pulmonary disease
Which hospitalized patients with COPD exacerbations should
receive antibiotics?
1 Patients with all three of the following symptoms:
increased dyspnoea, sputum volume and sputum puru-
lence (a type I Anthonisen exacerbation) [A2].
2 Patients with only two of the above three symptoms (a
type II Anthonisen exacerbation) when increased puru-
lence of sputum is one of the two cardinal symptoms
[A2].
3 Patients with a severe exacerbation that requires invasive
or non-invasive mechanical ventilation [A2].
4 Antibiotics are generally not recommended in Anthonis-
en type II without purulence and type III patients (one or
less of the above symptoms) [A2].
New information. Recommendation not changed [366–373].
What stratiﬁcation of patients with COPD exacerbation is recom-
mended to direct treatment? Group A: admitted to hospital
without risk factors for P. aeruginosa infection [A3].
Group B: admitted to hospital with risk factors for P. aeru-
ginosa [A3].
New information. Recommendation reworded, but not
changed [374–378].
What are the risk factors for P. aeruginosa? P. aeruginosa
should be considered in the presence of at least two of the
following.
1 Recent hospitalization [A3].
2 Frequent (>4 courses per year) or recent administration
of antibiotics (last 3 months) [A3].
3 Severe disease (FEV1 <30%) [A3].
4 Oral steroid use (>10 mg of prednisolone daily in the
last 2 weeks) [A3] [83,379–381].
Which microbiological investigations are recommended for the
hospitalized patient with COPD exacerbation? ‘Sputum cultures
or endotracheal aspirates (in mechanically ventilated patients)
should be obtained and are a good alternative to broncho-
scopic procedures for evaluation of the bacterial burden by
potential pathogenic microorganisms’ [A3].
Recommendation modiﬁed [84,367,382–388].
Which initial antimicrobial treatments are recommended for
patients admitted to hospital with COPD exacerbation?
1 In patients without risk factors for P. aeruginosa sev-
eral options for antibiotic treatment are available. The
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selection of one or other antibiotic should depend on the
severity of the exacerbation, local pattern of resistances,
tolerability, cost and potential compliance. Co-amoxiclav
is recommended while levoﬂoxacin and moxiﬂoxacin are
alternatives [A2].
2 In patients with risk factors for P. aeruginosa, ciproﬂoxacin
(or levoﬂoxacin 750 mg/24 h or 500 mg twice daily) is
the antibiotic of choice when the oral route is available.
When parenteral treatment is needed, ciproﬂoxacin or a
b-lactam with antipseudomonal activity are the options
available. The addition of aminoglycosides is optional [A2].
3 The use of the oral or intravenous route should be
guided by the stability of the clinical condition and the
severity of exacerbation. Switch (intravenous to oral)
should be done by day three of admission if the patient is
clinically stable [A3] [389–391].
How should the non-responding patient with COPD exacerbation
be assessed?
1 After close re-evaluation of non-infectious causes of fail-
ure (i.e. inadequate medical treatment, embolisms, cardiac
failure, other) a careful microbiological reassessment, as
mentioned in the section on microbiological diagnosis,
should be considered [C3].
2 Change to an antibiotic with good coverage against P. aeru-
ginosa, S. pneumoniae resistant to antibiotics and non-fer-
menters, and subsequent adjustment of the new antibiotic
treatment according to microbiological results, should be
considered for treatment in cases of failure [C3].
New information. Recommendation not changed [392].
Exacerbations of bronchiectasis
General recommendations for exacerbations of bronchiectasis.
1 Periodic surveillance of colonization should be consid-
ered [B3].
2 Antibiotic treatment should be given to patients with
exacerbations [B3].
3 Obtaining a sputum sample for culture before starting
antibiotic treatment should be done in most cases and
particularly in those requiring hospitalization [B3].
4 For empirical antibiotic treatment, patients should be
stratiﬁed according to the potential risk of Pseudomonas
spp infection [B3] (see What are the risk factors for
P. aeruginosa, above). Recommended antibiotics are sum-
marized in the box below.
5 Empirical antibiotics should be adjusted or modiﬁed
according to sputum culture results [A3].
New information. Recommendation not changed [393,394].
What antibiotics are recommended for exacerbations of bronchi-
ectasis? [C4].
Oral treatment Parenteral treatment
No risk of
Pseudomonas spp
Amoxicillin-clavulanate
Moxiﬂoxacin
Levoﬂoxacin
Risk of
Pseudomonas sppa
Ciproﬂoxacinb Ceftazidime or
carbapenem or
piperacillin-tazobactam
aUse the same criteria mentioned for chronic obstructive pulmonary disease
exacerbation.
bLevoﬂoxacin 750 mg/24 h or 500 mg twice daily is an alternative.
Refs. [88, 393,394].
Prevention
Prevention by methods other than vaccination
Does oral immunization with bacterial extracts prevent LRTI? In
patients with chronic bronchitis (CB) or COPD, H. inﬂuenzae
oral vaccine [B1] or bacterial extracts (OM-85 BV) [B2]
should not be given.
New information. Recommendation not changed [395–398].
What is the role of prophylactic antibiotic therapy in chronic bron-
chitis or COPD? In patients with CB or COPD, oral or par-
enteral antibiotics should not be given for prevention
[A1].
New information. Recommendation not changed [399–
401].
What is the role of prophylactic antibiotic therapy in patients
with COPD or bronchiectasis? (a) COPD: the use of nebulized
antibiotics or intermittent long-term macrolide therapy is
not recommended in COPD patients in general [C4]
[402].
(b) Bronchiectasis—nebulized antibiotics: there is not enough
evidence to recommend the use of nebulized antibiotics
(tobramycin) in non-cystic ﬁbrosis-bronchiectasis [C2]
[403,404].
(c) Bronchiectasis—macrolides: there is not enough evidence
to recommend the use of intermittent long-term macrolide
therapy in non-cystic ﬁbrosis-bronchiectasis in general [C2]
[405,406].
Does antibiotic treatment of upper respiratory tract infections pre-
vent LRTI? ‘Antibiotics should not be given as treatment for
URTI to prevent LRTI’ [A1].
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No new information. Recommendation not changed.
Does treatment with inhaled steroids or long-acting beta-2-agon-
ists or long-acting anti-muscarinics prevent LRTI? Inhaled ste-
roids [B1] or long-acting beta-2-agonists [C4] or long-acting
anti-muscarinics [C4] should not be used to prevent LRTI
(this does not mean that they might not prevent exacerbations
of COPD, which is an issue beyond the scope of this
document).
No new information. Recommendation not changed.
Does regular physiotherapy prevent LRTI? Physiotherapy should
not be used as a preventive approach against LRTI [C4].
No new information. Recommendation not changed.
Do antiviral substances prevent inﬂuenza virus infection? Pre-
vention of inﬂuenza by antiviral substances should only
be considered in special situations (for example in out-
breaks in closed communities during inﬂuenza seasons)
[A1]. In the case of seasonal inﬂuenza outbreaks or a pan-
demic situation the national recommendations should be
followed.
New information. Recommendation not changed [407].
Are oral mucolytics useful for the prevention of LRTI? In
patients with bronchiectasis, oral mucolytics should not be
used for prevention of LRTI [B1]. Prescription of oral muco-
lytics through the winter months should be considered for
those who have frequent or prolonged exacerbations, or
those who are repeatedly admitted to hospital with exacer-
bations of COPD and for whom inhaled corticosteroids
(ICS) are not prescribed [B1] [408].
Is there evidence that homeopathic substances prevent LRTI?
Homeopathic substances should not be used as a preventive
measure against LRTI [C4].
New information Recommendation not changed [409–
411].
Oral care in nursing homes. Intensiﬁed oral care in nurs-
ing home residents should be considered as a preventive
measure to reduce the incidence of pneumonia and the
risk of death from pneumonia in these patients [B1] [412–
414].
Are there commonly used medications decreasing the risk of
LRTI or CAP? Since the last version of these recommen-
dations a variety of commonly used drugs has been investi-
gated with regard to their potential to decrease the risk of
LRTI or CAP. These drugs are: inhaled steroids in COPD
patients and ACE inhibitors or statins in the general popu-
lation.
Inhaled steroids in COPD patients. Inhaled steroids might
decrease the risk of acute exacerbation in subgroups of
COPD patients, but they do not decrease the risk of LRTI.
In fact, they seem to increase the risk of LTRI/CAP in COPD
patients [415–419].
Statin use in the general population and the risk of CAP and
death from CAP. The use of statins and/or ACE inhibitors in
the general population has been investigated with regard to
their potential to decrease the risk of CAP or CAP-related
death.
The use of statins and/or ACE inhibitors might decrease
the risk of CAP or CAP-related death in the general popula-
tion. There are many more data for statins then for ACE
inhibitors [420–425].
Recommendations for inﬂuenza vaccination
Should inﬂuenza vaccine be used to prevent LRTI?
1 Inﬂuenza vaccine should be given yearly to persons at
increased risk of complications due to inﬂuenza [A2].
Vaccination should be carried out for immunocompetent
adults belonging to one, or more, of the following cate-
gories: age >65 years, institutionalization, chronic cardiac
diseases, chronic pulmonary diseases, diabetes mellitus,
chronic renal diseases, haemoglobinopathies, and women
who will be in the second or third trimester of preg-
nancy during the inﬂuenza season [8].
2 Repeated vaccinations are safe and do not lead to a
decreased immune response [B1].
3 In adults, inactivated, rather than live attenuated, vaccine
should be used [A1].
4 Yearly vaccination should be carried out for health care
personnel, especially in settings where elderly persons or
other high-risk groups are treated [B2].
5 General vaccination of all healthy adults should not be
carried out in the absence of robust cost-effectiveness
data for vaccination [B1] [426–441].
Recommendations for pneumococcal vaccination
Should pneumococcal vaccine be used to prevent LRTI?
1 The 23-valent polysaccharide pneumococcal vaccine pre-
vents invasive pneumococcal disease in older persons
and in other high-risk groups and should be given
to all adult persons at risk for pneumococcal disease
[A1].
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2 Risk factors for pneumococcal disease are age >65 years,
institutionalization, dementia, seizure disorders, conges-
tive heart failure, cerebrovascular disease, chronic
obstructive pulmonary disease, history of a previous pneu-
monia, chronic liver disease, diabetes mellitus, functional
or anatomical asplenia, and chronic cerebrospinal
ﬂuid leakage [B3]. Although smoking seems to be a signiﬁ-
cant risk factor in otherwise healthy younger adults, mea-
sures aimed at reducing smoking and exposure to
environmental tobacco smoke should be preferred in this
group.
3 Revaccination, once and not earlier than 5 years after
primary vaccination, should be performed in asplenic
patients and can be considered in the elderly and other
high-risk groups [B3].
4 There are not enough data to give any recommendations
concerning the use of conjugate pneumococcal vaccine in
adults [442–473].
Recommendations for implementation. Active interventions
should be used to enhance vaccination with either or both
of the vaccines, in order to achieve an adequate vaccination
coverage of the targeted population [A1] [474–477].
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